8 SEP 2008  Interim Results, Half Year Ended 30 JUN 08

ABI demonstrates that the Company has delivered its first net profit since incorporation.  Revenues of $3,433,129 represent a 61% increase over revenues in the same period last year; Company is long-term debt-free.

26 JUN 2008 ABI Signs New Distribution Agreement with Trinity Biotech 

ABI has appointed Trinity Biotech plc as another partner for the distribution of the Company's PIFA® Heparin/Platelet Factor-4 Rapid Assay (HPF4) in the USA and German markets.  Trinity Biotech is a specialist in the marketing and distribution of clinical diagnostic products.